Lapatinib
ATC L01EH01 · 7 markets · 12 records
HK 4 records · 1 strengths
Records without a stated strength · 1 Lapatinib、LAPATINIB STADA、TYKERB
ES 2 records · 1 strengths
- 250 mgtabletLAPATINIB STADATyverb 250mg tablets
GB 1 records · 1 strengths
- 250 mgtabletTyverb 250mg tablets
AU 1 records · 1 strengths
- 250 mgtabletTYKERB
CN 1 records · 1 strengths
- 250 mgtablet泰立沙甲苯磺酸拉帕替尼
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 Tyverb 250mg tablets
| Strength / form / release | GB | AU | CN | ES | HK | EU |
|---|---|---|---|---|---|---|
| 250 mgRecorded as: 0.25 g tablet | Tyverb 250mg tablets | TYKERB | 泰立沙甲苯磺酸拉帕替尼 | LAPATINIB STADA Tyverb 250mg tablets | ||
unknown | Lapatinib LAPATINIB STADA TYKERB | Tyverb 250mg tablets |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.